$TTAM

TTAM Maintained by Citigroup -- Price Target Lowered to $18.00

Citigroup maintained a 'Buy' rating for Titan America (TTAM) but lowered its price target from $21.00 to $18.00. The company's P/E ratio is 13.94x, below its 5-year median, and its GF Score™ is 22/100, indicating financial weaknesses. Insider activity shows no recent changes. TTAM operates in the building materials sector with a market cap of $2.47 billion.

Original reporting
Published Oct 2, 2026, 6:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 7:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TTAM
Bearish
high confidence
Mentioned
$TTAM
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$TTAMBearishMed
01

Why it matters

Analyst target reduction may prompt short‑term selling, but the maintained 'Buy' rating could attract value‑seeking investors.

02

Market read

The price‑target cut is the primary new information, offering a modest trading signal for TTAM.

03

What to watch

Potential cost‑inflation pressures in raw material inputs and upcoming infrastructure spending could support the stock despite the lower target.

Relevance 7/10Novelty 7/10Timing: today

Background

Titan America operates in the building‑materials segment, producing cement, aggregates, and ready‑mix concrete for the eastern U.S.

Company-level read

Ticker impact

$TTAMBearishHigh confidence
Context

Citigroup lowered its price target for Titan America (TTAM) from $21.00 to $18.00, a 14.3% reduction.

Expected impact

likely downside as investors price in the lower target

Evidence & confidence

Analyst price‑target cuts historically trigger sell pressure, especially when the rating remains unchanged.

Market effects

Basic Materials sector may see modest repricing as peers' valuations are compared to TTAM's new target.

U.S. construction‑materials market could experience slight sentiment drag.

Limited; impact confined to TTAM and its immediate peers.

Counterpoint

The unchanged 'Buy' rating may indicate that the target cut is a temporary adjustment rather than a fundamental downgrade.

Key entities

  • Titan America

    U.S. building‑materials producer (ticker TTAM).

  • Citigroup

    Issued the price‑target downgrade.

Related articles

$CLYMHighAI 8/10

Climb Bio reports early data on budoprutug for kidney diseases

Climb Bio (CLYM) presented Phase 2 trial data for budoprutug, an anti-CD19 antibody, showing B-cell depletion and PLA2R antibody reductions in kidney disease patients. The 200 mg dose achieved 70% mean antibody reduction, with 5/13 patients in remission. The 600 mg dose showed deeper B-cell depletion. The drug was well-tolerated. Climb Bio expects more data in 2027. Primary membranous nephropathy affects 75,000 people in the U.S. without FDA-approved treatments.

$AMGNHigh

Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study

Amgen's Phase III trial showed that IMDELLTRA plus IMFINZI reduced death risk by 58% vs. IMFINZI alone in extensive-stage small-cell lung cancer, with a hazard ratio of 0.42. The combo also improved progression-free survival and response rates. Amgen plans global regulatory submissions and further studies. According to the company, adverse events were manageable.

$AMGNMed

Amgen Drug Combination Cuts Lung Cancer Death Risk by 58%

Amgen announced that a Phase 3 trial of its drug Imdelltra combined with AstraZeneca's Imfinzi showed a 58% reduction in death risk for extensive-stage small cell lung cancer patients. Median overall survival increased to 21.1 months compared to 12.7 months for Imfinzi alone. Amgen plans to share these findings with global regulators.